ADC bioanalysis requires measuring free payload at picogram levels and intact antibody at microgram concentrations. That span pushes most labs toward multi-platform workflows, with separate instruments and method-development cycles for trace-detection and higher-concentration antibody work.
Ebru Selen, Biopharma Application Scientist at SCIEX, presented data showing the full range is addressable on a single platform. She ran all three assay modes for trastuzumab deruxtecan on a SCIEX 7500+ using a shared Phenomenex Kinetex C18 column—free payload LLOQ at 0.005 ng/mL through to total antibody spanning four orders of magnitude with R² = 0.997.
Download this executive summary to learn:
- Which sample preparation strategy—protein precipitation, immunocapture with papain cleavage, or trypsin digest—applies to each analyte class and why
- Why front-end system stability across extended sample queues matters more than peak sensitivity specifications
- What shared mobile phases across assays reveal about where matrix effects end and antibody selectivity begins
Meet the Expert:
 | Ebru Selen Application Scientist, SCIEX Ebru earned her Ph.D. at the University of Wisconsin–Madison and completed postdoctoral training at Johns Hopkins School of Medicine, developing mass spectrometry and NMR methods to study liver metabolism. At SCIEX, she builds next-generation bioanalytical workflows for pharmaceutical drug development. |
